title: [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
abstract: A 53-year-old woman with left breast tumor was diagnosed as bilateral breast cancer(left; T3N3M0, Stage III C/right; T2N0M0, Stage II )in our hospital, both of which were revealed as invasive ductal carcinoma shown to be ER-negative, PgR negative and HER2-positive by core needle biopsy. In December 2004, paclitaxel and trastuzumab combination therapy was tried, but she went into shock just during administration of paclitaxel, and this therapy was discontinued. After that the triweekly CTF therapy was tried as an anthracycline containing regimen, and the lymph node metastases obtained a complete response after a month and a 38. 5% reduction of left primary breast tumor, which was the best response observed after three months. Time to progression was prolonged to 7 months(9 cycles). Although febrile neutropenia occurred in the first cycle, the therapy could be continued safely thereafter as an outpatient. Anthracycline-containing regimens are likely to be avoided because of the difficulty of combining with trastuzumab in the treatment of HER2 overexpressing advanced/metastatic breast cancer. But the CTF therapy of less cardiotoxicity and less alopecia, can expect longer use and better QOL as an alternative for HER2 overexpressing advanced/metastatic breast cancer patients.
authors.affiliation: Dept. of Breast and Thyroid Surgery, Kawasaki Medical School.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oota
authors.forename: Sayaka
authors.initials: S
authors.lastname: Fujii
authors.forename: Toshirou
authors.initials: T
authors.lastname: Shimo
authors.forename: Akiko
authors.initials: A
authors.lastname: Miyake
authors.forename: Mari
authors.initials: M
authors.lastname: Seki
authors.forename: Tsunehisa
authors.initials: T
authors.lastname: Nomura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Shigeo
authors.initials: S
authors.lastname: Shiiki
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nakashima
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012769:Shock / Q000139:chemically induced
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D004317:Doxorubicin; D005472:Fluorouracil; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; C027260:pirarubicin; C508053:ERBB2 protein, human